Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA ; volume:9 ; number:1 ; day:24 ; month:9 ; year:2018 ; pages:1-10 ; date:12.2018
Nature Communications ; 9, Heft 1 (24.9.2018), 1-10, 12.2018
- Urheber
-
Paulson, K. G.
- Beteiligte Personen und Organisationen
-
Voillet, V.
McAfee, M. S.
Hunter, D. S.
Wagener, F. D.
Perdicchio, M.
Valente, W. J.
Koelle, S. J.
Church, C. D.
Vandeven, N.
Thomas, H.
Colunga, A. G.
Iyer, J. G.
Yee, C.
Kulikauskas, R.
Koelle, D. M.
Pierce, R. H.
Bielas, J. H.
Greenberg, P. D.
Bhatia, S.
Gottardo, R.
Nghiem, P.
Chapuis, A. G.
SpringerLink (Online service)
- DOI
-
10.1038/s41467-018-06300-3
- URN
-
urn:nbn:de:101:1-2018110414190266183232
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Paulson, K. G.
- Voillet, V.
- McAfee, M. S.
- Hunter, D. S.
- Wagener, F. D.
- Perdicchio, M.
- Valente, W. J.
- Koelle, S. J.
- Church, C. D.
- Vandeven, N.
- Thomas, H.
- Colunga, A. G.
- Iyer, J. G.
- Yee, C.
- Kulikauskas, R.
- Koelle, D. M.
- Pierce, R. H.
- Bielas, J. H.
- Greenberg, P. D.
- Bhatia, S.
- Gottardo, R.
- Nghiem, P.
- Chapuis, A. G.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combination immunotherapy: a road map
Applied immunoinformatics : HLA peptidome analysis for cancer immunotherapy
Combination Immunotherapy Strategies in Breast Cancer
Acquired mechanisms of immune escape in cancer following immunotherapy
Acquired resistance to immunotherapy in MMR-D pancreatic cancer
Immunotherapy for glioblastoma: the promise of combination strategies
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
Impact of FCGR Polymorphisms and KIR/HLA Mismatch on outcome following Immunotherapy of Neuroblastoma patients with ch14.18/CHO combination with IL-2
A target-agnostic combination immunotherapy synergistically cures established tumors
Combination strategies to maximize the benefits of cancer immunotherapy
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Combination immunotherapy: a road map
Applied immunoinformatics : HLA peptidome analysis for cancer immunotherapy
Combination Immunotherapy Strategies in Breast Cancer
Acquired mechanisms of immune escape in cancer following immunotherapy
Acquired resistance to immunotherapy in MMR-D pancreatic cancer
Immunotherapy for glioblastoma: the promise of combination strategies
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
Impact of FCGR Polymorphisms and KIR/HLA Mismatch on outcome following Immunotherapy of Neuroblastoma patients with ch14.18/CHO combination with IL-2
A target-agnostic combination immunotherapy synergistically cures established tumors
Combination strategies to maximize the benefits of cancer immunotherapy
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Combination immunotherapy: a road map
Applied immunoinformatics : HLA peptidome analysis for cancer immunotherapy
Combination Immunotherapy Strategies in Breast Cancer
Acquired mechanisms of immune escape in cancer following immunotherapy
Acquired resistance to immunotherapy in MMR-D pancreatic cancer
Immunotherapy for glioblastoma: the promise of combination strategies
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
Impact of FCGR Polymorphisms and KIR/HLA Mismatch on outcome following Immunotherapy of Neuroblastoma patients with ch14.18/CHO combination with IL-2
A target-agnostic combination immunotherapy synergistically cures established tumors
Combination strategies to maximize the benefits of cancer immunotherapy